AgeX Therapeutics (AGE) Stock Price, News & Analysis

Company Overview

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.22 to $16.51
• 52-Week Range: N/A
• Volume: 3,700 shs
• Average Volume: 3,849 shs
• Market Capitalization: $11.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AGE Stock Analysis - Frequently Asked Questions

When did AgeX Therapeutics' stock split?

AgeX Therapeutics shares split before market open on Monday, March 18th 2024.The 8-5 split was announced on Monday, March 18th 2024. The newly minted shares were distributed to shareholders after the market closes on Monday, March 18th 2024. An investor that had 100 shares of stock prior to the split would have 160 shares after the split.

What other stocks do shareholders of AgeX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AgeX Therapeutics investors own include Allena Pharmaceuticals (ALNA), Biocept (BIOC), Aadi Bioscience (AADI), Arbutus Biopharma (ABUS) and Adamis Pharmaceuticals (ADMP).

Company Calendar

• Today: 8/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NYSE:AGE
• CIK: 1708599
• Web: www.agexinc.com
• Phone: (510) 671-8370
• Fax: 510-871-4154
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($13.0282)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.80 million
• Net Margins: -10,424.65%
• Pretax Margin: -10,430.28%
• Return on Equity: N/A
• Return on Assets: -120.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.36

Sales & Book Value

• Annual Sales: $140 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($16.07) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,080,000
• Free Float: 1,008,000
• Market Cap: $11.99 million
• Optionable: Not Optionable
• Beta: 1.18